Biomea Fusion, Inc. (NASDAQ:BMEA) shares rose 6.61% to $1.45 in after-hours trading Monday after the company announced it would report Phase I results for its investigational oral GLP-1 candidate BMF-650 on Tuesday.

Biomea Fusion is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for diabetes and obesity.

BMF-650 Results Due Tuesday

Biomea Fusion said it will report results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonist, on Tuesday, Oct. 13.

The company scheduled a conference call and webcast for 4:30 p.m. ET (1:30 p.m. PT) to discuss the results. The live webcast will be available through the Investors and Media section of the company’s website, with a replay available afterward.

Biomea Fusion is also developing icovamenib, an oral small-molecule therapy for diabetes.

Trading Metrics, Technical Analysis

Biomea Fusion has a market capitalization of approximately $98.58 million.

Over the past year, the stock has traded between a 52-week high of $2.24 and a 52-week low of $0.87. The shares have fallen 17.58% over a 12-month period.

Benzinga Edge Stock Rankings indicate a negative price trend in the short term and positive trends in the medium and long term.

Price Action: In the regular session, Biomea Fusion shares fell 4.23% to close at $1.36 on Monday.

Photo: ZCOOL HelloRF / Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.